Technology Overview

Advancing the world's first immunization-based Growth Hormone (GH) and Insulin like Growth Factor-1 (IGF-1) treatments using novel second-generation somatostatin vaccines.

Somatostatin (also known as Growth Hormone Inhibiting Hormone) is the key regulator of the Growth Hormone (GH) release signaling cascade which leads to a number of important actions throughout the body including the increase of
IGF-1 (Insulin-like Growth Factor 1) levels.
The presence of active somatostatin in the blood inhibits the actions of Growth Hormone Releasing Hormone (GHRH) which controls the release
of GH.

Braasch's second-generation vaccine technology utilizes its patented, chimeric-based polypeptides to allow the immune system to temporarily attenuate, but not completely eliminate, the
mostly inhibitory actions of somatostatin. Our unique second-generation somatostatin vaccines thereby help the body to naturally release more of its own GH (from the pituitary), which then stimulates the release of IGF-1 (from the liver).

"Helping the body produce more of its own GH and IGF-1."